Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
Basal cell carcinoma (BCC) is the most common skin cancer. It generally has an indolent course with low rates of metastasis and mortality. However, BCC is locally invasive and can cause significant morbidity due to destructive local spread. We report our experience with a patient who was referred to...
Main Authors: | Pedro Carvalho Martins, Rita Valença Filipe, Rui Barbosa, Ivo Julião, Rosa Azevedo, Matilde Ribeiro, Abreu de Sousa |
---|---|
Format: | Article |
Language: | English |
Published: |
University of São Paulo
2019-10-01
|
Series: | Autopsy and Case Reports |
Subjects: | |
Online Access: | http://www.revistas.usp.br/autopsy/article/view/162876 |
Similar Items
-
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)
by: Nicolas Bertrand, MD, et al.
Published: (2021-05-01) -
Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
by: Maxwell G. Su, et al.
Published: (2020-09-01) -
Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion
by: Joseph Dodson, et al.
Published: (2022-12-01) -
Management of Basal Cell Carcinomas: Clinical Experience
by: İrfan Kara, et al.
Published: (2022-03-01) -
Reconstruction of the nasal columella using bilateral nasolabial flaps: case report
by: Marcelo Rosseto, et al.
Published: (2023-07-01)